Acute treatment of atrial fibrillation: Why and when to maintain sinus rhythm

American Journal of Cardiology

Volumn 81, Issue 5 A, 1998, Pages 3C-15C

  Waktare, Johan E P ^a   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

CARDIOVERSION; CONFERENCE PAPER; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; SINUS RHYTHM; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0032510395     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00181-7     Document Type: Conference Paper

References (102)

1. Ostrander LD Jr, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community. Tecumseh, Michigan. Circulation 1965;31:888-1898.
2. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-241.
3. Hill JD, Mottram EM, Killeen PD. Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age. J R Coll Gen Pract 1987;37: 172-173.
4. Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias - use of synchronized capacitor discharge. JAMA 1962;182:548-555.
5. Gallagher MG, Camm AJ. Classification of atrial fibrillation. Pacing Clin Electrophysiol 1997;20:1603-1605.
6. Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. (Abstr.) J Am Coll Cardiol 1992;19:41A.
7. Totaro R, Corridoni C, Marini C, Marsili R, Prencipe M. Transcranial Doppler evaluation of cerebral blood flow in patients with paroxysmal atrial fibrillation. Ital J Neurol Sci 1993;14:451-454.
8. Leitch JW, Klein GJ, Yee R, Leather RA, Kim YH. Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or vasomotor response? Circulation 1992;85:1064-1071.
9. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68:41-46.
10. Murgatroyd FD, O'Nunain S, Gibson SM, Ward DE, Camm AJ. The results of CRAFT-1: a multi-center, double-blind, placebo-controlled crossover study of digoxin in symptomatic paroxysmal atrial fibrillation. (Abstr.) J Am Coll Cardiol 1993;21:478A.
11. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchet EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 1994;74:826-829.
12. Jenkins LS, Ellenbogen K, Kay N, Giudici M, Jensen N, Martin R, Bubein R. Quality of life in patients with symptomatic atrial fibrillation. (Abstr.) Circulation 1995;92(suppl I):490.
13. Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, Oddone D, Gaggioli G. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994;74:242-246.
14. Kay GN, Bubien RS, Epstein AE, Plumb VJ. Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988;62:741-744.
15. Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, Hughes RA, Kistler JP. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med 1991;151:1944-1949.
16. Atwood JE, Myers JN, Sullivan MJ, Forbes SM, Sandhu S, Callaham P, Froelicher VF. The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation. Am Heart J 1989;118:913-918.
17. Ueshima K, Myers J, Morris CK, Atwood JE, Kawaguchi T, Froelicher VF. The effect of cardioversion on exercise capacity in patients with atrial fibrillation. Am Heart J 1993;126:1021-1024.
18. Gosselink AT, Crijns HJ, Van Den Berg MP, van den Broek SA, Hillege H, Landsman ML, Lie KI. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994;72:161-166.
19. Gosselink AT, Bijlsma EB, Landsman ML, Crijns HJ, Lie KI. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation. A 2-year follow-up. Eur Heart J 1994;15:1368-1372.
20. Lipkin DP, Frenneaux M, Stewart R, Stewart R, Joshi J, Lowe T, McKenna WJ. Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J 1988;59:572-577.
21. Van Gelder IC, Crijns HJ, Blanksma PK, Landsman ML, Posma JL, Van Den Berg MP, Meijler FL, Lie KI. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993;72:560-566.
22. Kubac G, Malowany L. Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion. Can J Cardiol 1992;8: 941-946.
23. Lundstrom T, Karlsson O. Improved ventilatory response to exercise after cardioversion of chronic atrial fibrillation to sinus rhythm. Chest 1992;102:1017-1022.
24. Resnekov L, McDonald L. Electroversion of lone atrial fibrillation and flutter including haemodynamic studies at rest and on exercise. Br Heart J 1971;33: 339-350.
25. Belli C, Severgnini B, Giudice N. Ergometric functional evaluation of heart disease patients in atrial fibrillation before and after electric conversion. Atti Soc Ital Cardiol 1969;2:10-13.
26. Obel IW, Zwi S, Goldman HI, Bramwell-Jones M. Effort tolerance before and after cardioversion. S Afr Med J 1968;42:1207-1211.
27. Kaplan MA, Gray RE, Iseri LT. Metabolic and hemodynamic responses to exercise during atrial fibrillation and sinus rhythm. Am J Cardiol 1968;22:543-549.
28. Shapiro W, Klein G. Alterations in cardiac function immediately following electrical conversion of atrial fibrillation to normal sinus rhythm. Circulation 1968;38:1074-1084.
29. Linde-Edelstam CM, Juhlin-Dannfelt A, Nordlander R, Pehrsson SK. The hemodynamic importance of atrial systole: a function of the kinetic energy of blood flow? Pacing Clin Electrophysiol 1992;15:1740-1749.
30. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-977.
31. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
32. Theiss W. Anticoagulants: when and how? Pacing Clin Electrophysiol 1994;17:1011-1015.
33. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967;29: 469-489.
34. Resnekov L, McDonald L. Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion. Br Heart J 1967;29:926-936.
35. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969;23:208-216.
36. Schulman S. Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group. J Intern Med 1994; 236:143-152.
37. Ezekowitz MD, James KE, Nazarian SM, Davenport J, Broderick JP, Gupta SR, Thadani V, Meyer ML, Bridgers SL. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995;92:2178-2182.
38. Petersen P, Madsen EB, Brun B, Pedersen F, Gyldensted C, Boysen G. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987;18:1098-1100.
39. Feinberg WM, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Intern Med 1990;150:2340-2344.
40. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
41. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE. Atrial enlargement as a consequence of atrial fibrillation. A prospective echo cardio graphic study. Circulation 1990;82:792-797.
42. Keren G, Etzion T, Sherez J, Zelcer AA, Megidish R, Miller HI, Laniado S. Atrial fibrillation and atrial enlargement in patients with mitral stenosis. Am Heart J 1987;114:1146-1155.
43. Petersen P, Kastrup J, Brinch K, Godtfredsen J, Boysen G. Relation between left atrial dimension and duration of atrial fibrillation. Am J Cardiol 1987;60: 382-384.
44. Leistad E, Christensen G, Ilebekk A. Effects of atrial fibrillation on left and right atrial dimensions, pressures, and compliances. Am J Physiol 1993;264: H1093-H1097.
45. Investigators TSPiAF. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
46. Welikovitch L, Lafreniere G, Burggraf GW, Sanfilippo AJ. Change in atrial volume following restoration of sinus rhythm in patients with atrial fibrillation: a prospective echo cardio graphic study. Can J Cardiol 1994;10:993-996.
47. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989;13:617-623.
48. Mahlich J, Schweizer W, Burkart F. Atrial function after cardioversion for atrial fibrillation. Br Heart J 1973;35:24-27.
49. Shapiro EP, Effron MB, Lima S, Ouyang P, Siu CO, Bush D. Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. Am J Cardiol 1988;62:1202-1207.
50. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994;23:307-316.
51. Abascal VM, Dubrey S, Ochoa MR, Davidoff R, Falk RH. Electrical vs pharmacologic cardioversion in atrial fibrillation: does the atrium really care? (Abstr.) Circulation 1995;92(Suppl I):591.
52. Dodds GA, Wilkinson WE, Greenfield RA, Natale A, Kisslo J, Pritchett EL. Transthorasic cardioversion does not affect atrial mechanical function. (Abstr.) Circulation 1995;92(Suppl I):591.
53. Rodriguez LM, Smeets JL, Xie B, de Chillou C, Cheriex E, Pieters F, Metzger J, den Dulk K, Wellens HJ. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993;72:1137-1141.
54. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
55. Haiat R, Halphen C, Stoltz JP, Leroy G, Soussana C. Auricular fibrillation: a cause of reversible myocardiopathy. Ann Cardiol Angeiol 1987;36:417-419.
56. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med 1988;85:242-244.
57. Van Den Berg MP, van Veldhuisen DJ, Crijns HJ, Lie KI. Reversion of tachycardiomyopathy after beta-blocker. (Letter.) Lancet 1993;341:1667.
58. Olsson SB, Carlson J, Holm M, Nilsson A. Atrioventricular nodal function in atrial fibrillation: what is the optimun ventricular rate? In: Murgatroyd FD, Camm AJ, eds. Nonpharmacological Management of Atrial Fibrillation. Armonk, NY: Futura Publishing, 1996:55-64.
59. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
60. Dalzell GW, Anderson J, Adgey AA. Factors determining success and energy requirements for cardioversion of atrial fibrillation. Q J Med 1990;76:903-913.
61. Morris JJJ, Peter RH, McIntosh HD. Electrical cardioversion of atrial fibrillation: immediate and long term results and selection of patients. Ann Intern Med 1966;65:216-231.
62. Levy S, Lauribe P, Dolla E, Kou W, Kadish A, Calkins H, Pagannelli F, Moyal C, Bremondy M, Schork A, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992;86: 1415-1420.
63. Ewy GA. The optimal technique for electrical cardioversion of atrial fibrillation. Clin Cardiol 1994;17:79-84.
64. Pelesla B. Optimal parameters of electrical impulses for defibrillation by capacitor discharge. Circ Res 1966;18:10-17.
65. Lown B, Kleiger R, Wolff G. The technique of cardioversion. Am Heart J 1964;67:282-284.
66. Resnekov L, McDonald L. Appraisal of electro conversion in treatment of cardiac dysrhythmias. Br Heart J 1968;30:786-811.
67. Kerber RE, Jensen SR, Grayzel J, Kennedy J, Hoyt R. Elective cardioversion: influence of paddle-electrode location and size on success rates and energy requirements. N Engl J Med 1981;305:658-662.
68. Ewy GA, Hellman DA, McClung S, Taren D. Influence of ventilation phase on transthoracic impedance and defibrillation effectiveness. Crit Care Med 1980; 8:164-166.
69. Van Gelder IC, Crijns HJGM, Van Gilst WH, De Langen CD, Van Wijk LM, Lie KI. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989;63:112-114.
70. Rossi M, Lown B. The use of quinidine in cardioversion. Am J Cardiol 1967;19:234-238.
71. Blevins RD, Kerin NZ, Benaderet D, Frumin H, Faitel K, Jarandilla R, Rubenfire M. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987;147:1401-1404.
72. Skoularigis J, Rothlisberger C, Skudicky D, Essop MR, Wisenbaugh T, Sareli P. Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol 1993;72:423-427.
73. Sopher SM, Murgatroyd FDM, Slade AKB, Blankoff I, Ward DE, Rowland E, Camm AJ. Low energy transvenous cardioversion of atrial fibrillation resistant to transthoracic shocks. Br Heart J 1996;75:635-638.
74. Kerber RE, Grayzel J, Hoyt R, Marcus M, Kennedy J. Transthoracic resistance in human defibrillation. Influence of body weight, chest size, serial shocks, paddle size and paddle contact pressure. Circulation 1981;63:676-682.
75. Baker BM, Botteron GW, Smith JM. Low-energy internal cardioversion for atrial fibrillation resistant to external cardioversion. J Cardiovasc Electrophysiol 1995;6:44-47.
76. Schmitt C, Ammer R, Alt E, Pasquantonio J, Plewan A, Schomig A. Energy requirement for intracardiac low-energy cardioversion of chronic atrial fibrillation: comparison of different lead positions. (Abstr.) Pacing Clin Electrophysiol 1996;19:657.
77. Waris E, Kreus K, Salokannel J. Factors influencing the persistence of sinus rhythm after DC shock treatment of atrial fibrillation. Acta Medicine Scandinavia 1971;189:161-166.
78. Dethy M, Chassat C, Roy D, Mercier LA. Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol 1988;62:723-726.
79. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994;89:724-730.
80. Brodsky MA, Allen BJ, Capparelli EV, Luckett CR, Morton R, Henry WL. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol 1989;63:1065-1068.
81. Flugelman MY, Hasin Y, Katznelson N, Kriwisky M, Shefer A, Gotsman MS. Restoration and maintenance of sinus rhythm after mitral valve surgery for mitral stenosis. Am J Cardiol 1984;54:617-619.
82. Hall JI, Wood DR. Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine. Br Heart J 1968;30:84-90.
83. Brodsky MA, Allen BJ, Walker CJ, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572-575.
84. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124-127.
85. Vitolo E, Tronci M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;36: 431-444.
86. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68:335-341.
87. Antman EM, Beamer AD, Cantillon C, McGowanN, Friedman PL. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698-707.
88. Sulke N, Kamalvand K, Tan K, Smeeton N, Stafford P, Vincent R. A prospective evaluation of recurrent atrial endocardial defibrillation in patients with refactory chronic atrial fibrillation and flutter. (Abstr.) Heart 1996;75:P42.
89. Black IW, Fatkin D, Sagar KB, Khandheria BK, Leung DY, Galloway JM, Feneley MP, Walsh WF, Grimm RA, Stollberger C, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: a multicenter study. Circulation 1994;89: 2509-2513.
90. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992;102(4 suppl):426S-433S.
91. Pomfret SM, Beasley CR, Challenor V, Holgate ST. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. Clin Sci 1988;74:351-357.
92. Lang RM, Klein HO, Weiss E, David D, Sareli P, Levy A, Guerro J, Di Segni E, Kaplinsky E. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983;83:491-499.
93. Dahlstrom CG, Edvardsson N, Nasheng C, Olsson SB. Effects of diltiazem, propranolol, and their combination in the control of atrial fibrillation. Clin Cardiol 1992;15:280-284.
94. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988;9:777-781.
95. Atwood JE, Myers JN, Sullivan MJ, Forbes SM, Pewen WF, Froelicher VF. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 1988;93:20-25.
96. Matsuda M, Matsuda Y, Yamagishi T, Takahashi T, Haraguchi M, Tada T, Kusukawa R. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res 1991;25:453-457.
97. Ahuja RC, Sinha N, Saran RK, Jain AK, Hasan M. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis - a randomised cross-over study. Int J Cardiol 1989;25:325-331.
98. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989;13:1-6.
99. Feld GK, Fleck RP, Fujimura O, Prothro DL, Bahnson TD, Ibarra M. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994;90:2299-2307.
100. Marshall HJ, Harris Z, Griffith MJ, Gammage MD. Atrioventricular node ablation and implantation of dual chamber mode switching pacemakers for paroxysmal atrial fibrillation - effects on quality of life, exercise cappacity and left ventricular systolic function. (Abstr.) Heart 1996;5(Suppl 1):P65.
101. Zehender M, Faber T, Jeron A, Fuhrmann P, Muller J. Is cardioversion of atrial fibrillation the ultimate longterm goal? (Abstr.) Circulation 1995;92(suppl I):755.
102. Disch DL, Greenberg ML, Holzberger PT, Malenka DJ, Birkmeyer JD. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994;120:449-457.